A Phase 2/3 interventional study of AXS-05 and Bupropion in Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease and Agitation,Psychomotor, sponsored by Axsome Therapeutics, Inc.. Completed at 78 sites in 2 countries. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Axsome Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 263rd largest by enrollment of the 1,609 interventional ones that give a count, is one of 69 that started in 2017, is one of 42 in phase 2/3, and was the 874th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 65 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,940 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 69 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 366 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,609 interventional studies, 160 across the 309 observational. Of the 1,378 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,940 have an industry lead sponsor. The 10 most frequent:
Axsome Therapeutics, Inc. is the lead sponsor of 37 studies on the registry; 12 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
Axsome Therapeutics, Inc. has 5 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
165 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 165 to your calendar (.ics) → With an account.
Among the 1,940 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.
Key Inclusion Criteria:
Exclusion Criteria:
AXS-05 tablets taken by mouth for 5 weeks.
Drug: AXS-05
Bupropion tablets taken by mouth for 5 weeks.
Drug: Bupropion
Placebo tablets taken by mouth for 5 weeks.
Drug: Placebo
Change in CMAI Total Score
The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver-rated questionnaire that assesses the frequency of agitation-related and disruptive behaviors in subjects with dementia. The scale contains 29 behaviors or items organized into four subscales: physically aggressive, physically non-aggressive, verbally aggressive, and verbally non-aggressive. The CMAI is administered by interviewing the caregiver and asking him or her to rate the frequency with which the subject manifests each behavior using a seven-point scale: 1=never (better outcome), 7=several times an hour (worse outcome). The CMAI total score is the sum of the scores for all of the items in the CMAI. CMAI total scores range from a minimum of 29 (better outcome) to a maximum of 203 (worse outcome).
Time frame: 5 weeks
| Milestone | AXS-05 | Bupropion | Placebo |
|---|---|---|---|
| Started | 159 | 49 | 158 |
| Safety population | 159 | 49 | 158 |
| Mitt population | 152 | 49 | 156 |
| Completed | 137 | 48 | 136 |
| Not completed | 22 | 1 | 22 |
The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver-rated questionnaire that assesses the frequency of agitation-related and disruptive behaviors in subjects with dementia. The scale contains 29 behaviors or items organized into four subscales: physically aggressive, physically non-aggressive, verbally aggressive, and verbally non-aggressive. The CMAI is administered by interviewing the caregiver and asking him or her to rate the frequency with which the subject manifests each behavior using a seven-point scale: 1=never (better outcome), 7=several times an hour (worse outcome). The CMAI total score is the sum of the scores for all of the items in the CMAI. CMAI total scores range from a minimum of 29 (better outcome) to a maximum of 203 (worse outcome).
| score on a scale | AXS-05 | Bupropion | Placebo |
|---|---|---|---|
| Change in CMAI Total Score | -15.4 ± 1.25 | -10.0 ± 3.02 | -11.5 ± 1.10 |
Collected over Adverse events were collected from the Baseline visit through 30 days after the last study visit (up to 10 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AXS-05 | 0/159 (0%) | 5/159 (3.1%) | 33/159 (20.8%) |
| Bupropion | 1/49 (2%) | 4/49 (8.2%) | 17/49 (34.7%) |
| Placebo | 1/158 (0.6%) | 9/158 (5.7%) | 24/158 (15.2%) |
| Event | AXS-05 | Bupropion | Placebo |
|---|---|---|---|
| Abdominal discomfortGastrointestinal disorders | 0/159 | 1/49 | 0/158 |
| Abdominal painGastrointestinal disorders | 0/159 | 1/49 | 0/158 |
| Urinary tract infectionInfections and infestations | 0/159 | 1/49 | 1/158 |
| DementiaNervous system disorders | 0/159 | 1/49 | 0/158 |
| Oedema peripheralGeneral disorders | 0/159 | 0/49 | 1/158 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/159 | 0/49 | 1/158 |
| DehydrationMetabolism and nutrition disorders | 0/159 | 0/49 | 1/158 |
| Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/159 | 0/49 | 1/158 |
| Dementia Alzheimer's typeNervous system disorders | 1/159 | 0/49 | 1/158 |
| SyncopeNervous system disorders | 0/159 | 0/49 | 1/158 |
| Event | AXS-05 | Bupropion | Placebo |
|---|---|---|---|
| FallInjury, poisoning and procedural complications | 4/159 | 7/49 | 3/158 |
| FatigueGeneral disorders | 3/159 | 5/49 | 2/158 |
| DizzinessNervous system disorders | 10/159 | 5/49 | 5/158 |
| SomnolenceNervous system disorders | 13/159 | 2/49 | 5/158 |
| DiarrheaGastrointestinal disorders | 7/159 | 3/49 | 7/158 |
| HeadacheNervous system disorders | 6/159 | 3/49 | 4/158 |
| InsomniaPsychiatric disorders | 1/159 | 3/49 | 3/158 |
| Age, Continuous(years) | AXS-05 | Bupropion | Placebo | Total |
|---|---|---|---|---|
| Mean | 75.3 ± 5.71 | 76.4 ± 6.13 | 74.6 ± 6.11 | 75.1 ± 5.95 |
| Sex: Female, Male(Participants) | AXS-05 | Bupropion | Placebo | Total |
|---|---|---|---|---|
| Female | 91 | 22 | 92 | 205 |
| Male | 68 | 27 | 66 | 161 |
| Race/Ethnicity, Customized(Participants) | AXS-05 | Bupropion | Placebo | Total |
|---|---|---|---|---|
| Race — American Indian or Alaska Native | 2 | 0 | 0 | 2 |
| Race — Asian | 2 | 0 | 1 | 3 |
| Race — Black or African American | 12 | 5 | 25 | 42 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Race — Other | 1 | 1 | 0 | 2 |
| Race — Unknown or Not Reported | 1 | 0 | 1 | 2 |
| Race — White | 141 | 43 | 130 | 314 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Apr 2020, 33 months.
Results were first posted in Sep 2023, 3 years 4 months after primary completion.
Of 28 phase 2/3 interventional studies under Alzheimer Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 59. This study's 33 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05